Professor Mitchell completed a PhD in Pharmacology with Sir Professor John R Vane (FRS, Nobel Laureate) and Dr Gilberto De Nucci 1990 before joining Professor Ferid Murad (NAS USA, Nobel Laureate) as a fellow of Northwestern University (Chicago, USA) for her postdoctoral training in the biochemistry of nitric oxide synthase. She returned to work with John Vane on the pharmacology of cyclo-oxygenase isoforms before joining the group of Professor Timothy Williams at the National Heart and Lung Institute, now part of Imperial College.
Professor Mitchell was awarded a Wellcome Trust Career Development Fellowship in 1997 and the Novartis Prize for Pharmacology in 1999 for her contribution to the field of cyclo-oxygeanse biology. Since this time, Professor Mitchell has led her own group - Cardiothoracic Pharmacology - consisting of academics, clinicians, postdoctoral fellows and undergraduate/postgraduate students.
Professor Mitchell is amongst the top 1% of cited pharmacologists world-wide and as such, is a member of Thomson Scientific Highlycited listings (isihighlycited.com) with more than 150 publications in peer reviewed journals.
Professor Mitchell was awarded the 2009 Rector’s Award for Excellence in Research Supervision and Elected Research Supervision Fellow.
Professor Mitchell was awarded the AstraZeneca Women in Pharmacology Prize in 2012. She talks about receiving the award here.
et al., EGF receptor (EGFR) inhibition promotes a slow-twitch oxidative, over a fast-twitch, muscle phenotype, Scientific Reports, ISSN:2045-2322
Mitchell JA, Kirkby NS, 2019, Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system., Br J Pharmacol, Vol:176, Pages:1038-1050
et al., 2019, Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2., J Clin Invest, Vol:130
et al., 2019, Preventing bronchopulmonary dysplasia: new tools for an old challenge, Pediatric Research, Vol:85, ISSN:0031-3998, Pages:432-441
Mitchell JA, Bishop-Bailey D, 2019, PPARβ/δ a potential target in pulmonary hypertension blighted by cancer risk., Pulm Circ, Vol:9, ISSN:2045-8932